linjc16/ctgov huggingface dataset:
Association Between Carotid Plaque Length and Cardiovascular Events

Study Overview
=================
Brief Summary
-----------------
This multicenter study involved 5 hospitals (Changhai Hospital; Yueyang Hospital of Shanghai University of Traditional Chinese Medicine; Gongli Hospital; Putuo Hospital of Shanghai University of Traditional Chinese Medicine; No. 904 Hospital of the PLA Joint Logistics Support Force Wuxi). The study enrolled 3637 patients with coronary atherosclerosis who were confirmed by coronary angiography from January 2017 through December 2018.

Detailed Description
-----------------
Patients with coronary atherosclerosis who were confirmed by coronary angiography were eligible for the study. Carotid ultrasonography was simultaneously performed, and carotid intima-media thickness (IMT), maximum thickness and length of all plaques were measured.

Official Title
-----------------
Association Between Carotid Plaque Length and Cardiovascular Events

Conditions
-----------------
Coronary Arteriosclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients≥18 years old, those who underwent carotid ultrasonography and first coronary angiography simultaneously. Exclusion Criteria: Patients with known coronary artery disease, previous coronary or carotid revascularization, missing carotid ultrasound or coronary angiography results.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Carotid plaque length<br>Patients underwent coronary angiography and carotid ultrasonography simultaneously | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major adverse cardiovascular events | A composite of cardiovascular death, myocardial infarction, and stroke | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incident cardiovascular events | A composite of cardiovascular death, myocardial infarction, stroke, and unplanned coronary artery revascularization | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Carotid Artery Ultrasound, Carotid Plaque, Coronary Artery Disease
SeaCare's Care Coordination for Diabetes Management in a Primary Care Office

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether it is possible to improve health outcomes for patients with Type II diabetes, a community-based health care agency will offer care coordination to half of a study group in a family practice office. The intervention will include assessing patients' status using two instruments: a depression screen (the PHQ9) and a motivation to change scale (the Patient Activation Measure, PAM). A masters-level social worker will counsel patients in the intervention group. Changes in patients' health status, PHQ9 scores and PAM scores over one year will be measured. Outcomes will be compared between the study group and the group without intervention.

Official Title
-----------------
Improved Management of Type II Diabetes in a Primary Care Office With Targeted Case Management

Conditions
-----------------
Type 2 Diabetes

Intervention / Treatment
-----------------
* Behavioral: care coordination


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diabetes type II Exclusion Criteria: Non-English speaking

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Care Coordination<br>Patients receive care coordination to improve their diabetes. | Behavioral: care coordination<br>* patients receive care coordination to improve their type II diabetes<br>|
| No Intervention: control<br>patients with type II diabetes receive usual health care | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Scores on PHQ9, PAM and health indicators |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Satisfaction with care coordination model. |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
diabetes
Effects of Hemoperitoneum Driven Carbon Monoxide on Post-Traumatic Stability and Platelet Aggregation

Study Overview
=================
Brief Summary
-----------------
Our objective is to determine whether or not the presence of hemoperitoneum in trauma patients is associated with increased Carbon Monoxide (CO) formation, and to determine if elevated Carbon Monoxide levels are associated with cardiovascular depression, impaired platelet aggregation, and/or multiple organ failure.

Official Title
-----------------
Effects of Hemoperitoneum Driven Carbon Monoxide on Post-Traumatic Stability

Conditions
-----------------
Hemoperitoneum

Intervention / Treatment
-----------------
* Procedure: expired air


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hospitalized males 18 years of age or older, Diagnosis of isolated blunt OR blunt and penetrating trauma, Admitted or expecting to be admitted to the Intensive Care Unit, On mechanical ventilation, and Written informed consent obtained Exclusion Criteria: Female gender, (Females will be excluded from this study as the menstrual cycle and other estrogen variations are known to be associated with cyclic changes in CO production adding a potential confounder to the interpretations of our findings.) Diagnosis of isolated penetrating trauma, Acute hemothorax or pneumothorax, Treatment with antiaggregants (ASA, clopidogrel, aggrenox or ticlopidine), Enrollment in another research study, Prisoners, Inability to perform CO measurement within 96 hours after hospital admission.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| no treatment<br> | Procedure: expired air<br>* collection of expired air from ventilator<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| •Establish a method for reliably measuring CO excretion in patients. |  | 96 hours |
A Prospective Study of Evaluation of Minor Bleeding and Utility of Bleeding Criteria in Acute-on-chronic Liver Failure Patients in China

Study Overview
=================
Brief Summary
-----------------
Ineffective hemostasis or a paradoxical prothrombotic state of Acute-on-chronic liver disease (ACLF) has been well established. However, the minor and major bleeding events has not been described yet. We observe the patients' major and minor bleeding events and use 4 criteria, which include BARC, ISTH, TIMI, Gusto ,to evaluate the incident rate of bleeding events in ACLF patients and pre-ACLF patients.

Official Title
-----------------
A Prospective Study of Evaluation of Minor Bleeding and Utility of Bleeding Criteria in Acute-on-chronic Liver Failure Patients in China

Conditions
-----------------
Liver Failure, Acute on Chronic, Hemostatic Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient with previously or undiagnosed chronic liver disease/cirrhosis; serum bilirubin higher than 3 mg/dl (51 mmol/L) or ALT>10ULN（male 300 U/L; female 200 U/L) Exclusion Criteria: those who had or been diagnosed hepatocellular carcinoma or other types of malignancies; pregnancy; obstructive biliary diseases or other disease lead to bilirubin evaluation; using steroid or immunosuppressant in 4 weeks; prior surgeries including splenectomy，subtotal splenectomy and disconnection，liver transplantation. combine with other disease lead to organ failure including heart failure (NYHA IV),respiratory failure（PaO2<60mmHg),renal insufficiency(CKD 5) and conscious disturbance (GCS<8)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 28-day progression | progressed to EASL or APASL defined ACLF or death | 28-day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| major bleeding event | major bleeding event happen | 90-day | 
| 28-day mortality | death within 28 days | 28-day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
liver failure
Usefulness of Multi-parametric, Quantitative MR Imaging for Staging of Hepatic Fibrosis in the Patients With Chronic Hepatitis

Study Overview
=================
Brief Summary
-----------------
Liver fibrosis has been considered as irreversible change. However, recent study showed that early stage liver fibrosis could be reversible and a lot of new drugs are now developing or developed including anti-viral treatment. Liver biopsy is considered as golden standard for the evaluation of liver fibrosis. But biopsy specimen through biopsy only consists of 1/50000 of the whole liver and heterogeneity of liver fibrosis, accurate diagnosis of liver fibrosis is still challenging. Furthermore, its invasive nature, repeated biopsy is practically almost impossible. Hence, non-invasive diagnosis of liver fibrosis is important. In this study we hypothesized that multi-parametric MR imaging including MR elastography, conventional DWI, and IVIM can predict changes of liver stiffness after anti-viral therapy in patients with chronic liver disease. We will enroll 60 biopsy-proven patients and perform multi-parametric MR imaging at the enrollment and one year later to evaluate changes in quantitative values in MR.

Conditions
-----------------
Liver Fibrosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who had chronic hepatitis Patients who underwent liver biopsy within 6 months Patients older than 18 years old Exclusion Criteria: patient who had pregnancy patient 18 or below 18 years old

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Liver fibrosis<br>patients who had chronic liver disease | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in quantitative values measured from Multi-parametric MRI before and after anti-viral treatment | Elasticity, conventional ADC value, IVIM ADC value, T2* value, T1 rho value will be compared before and after anti-viral treatment | 1 year after enrollment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Liver fibrosis, Elastography, MR Elastography, Quantitative imaging
Immunogenicity and Safety Study of Serum-Free Avonex

Study Overview
=================
Brief Summary
-----------------
To evaluate the immunogenicity of a serum-free pre-formulated solution of Avonex when given to interferon beta naive patients with relapsing/remitting multiple sclerosis.

Official Title
-----------------
A Multicenter, Open-Label Immunogenicity and Safety Study of a Serum-Free Pre-Formulated Solution of AVONEX (Interferon Beta-1a) Administered Intramuscularly to Patients With Relapsing/Remitting Multiple Sclerosis

Conditions
-----------------
Multiple Sclerosis

Intervention / Treatment
-----------------
* Drug: Interferon beta-1a


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must have a diagnosis of relapsing/remitting MS as defined by McDonald, et al15; criteria numbers 1-4. Must have an expanded disability status scale (EDSS) score between 0 and 5.5, inclusive. Must be able to understand and comply with the protocol. Exclusion Criteria: Has experienced a relapse within 2 months prior to Day 1. Relapses are defined as new or recurrent neurologic symptoms not associated with fever or infection, lasting at least 48 hours, and accompanied by new objective neurological findings upon examination by the investigator. History of any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease that would preclude therapy with interferon beta. Abnormal screening or baseline blood tests determined to be clinically significant by the investigator History of a seizure within 3 months prior to Day 1. History of suicidal ideation within 3 months prior to Day 1 or an episode of severe depression within 3 months prior to Day 1. Known allergy to natural rubber latex. Other inclusion and exclusion criteria apply as per protocol

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>serum-free avonex given IM | Drug: Interferon beta-1a<br>* serum free Avonex given IM once a week<br>* Other names: Avonex;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the immunogenicity of a serum-free pre-formulated solution of AVONEX® |  | Study duration is 20 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate the safety of a serum-free pre-formulated solution of AVONEX® |  | The study duration is 20 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
multiple sclerosis, interferon beta-1a, avonex
A Study of Lyrica as Treatment for Sleep Problems in Patients With Sleep Problems and Seizures

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the effects of pregabalin on sleep problems in patients with seizures.

Official Title
-----------------
Pregabalin BID Add-on Trial: a Randomized, Double-Blind, Placebo-Controlled Parallel-Group Single-Center Sleep EEG Study in Patients With Partial Seizures and Sleep Disturbance Part B: a Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study of Pregabalin Add-on Treatment

Conditions
-----------------
Sleep Deprivation, Epilepsies, Partial

Intervention / Treatment
-----------------
* Drug: Pregabalin
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Partial epileptic seizures Not taking more than 1 background antiepileptic drug at study entry Disturbed sleep Exclusion Criteria: More than 1 secondarily generalized tonic/clonic seizure per week on average over the previous 3 months Medical, psychological, or social conditions that could interfere with normal sleep

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Pregabalin<br> | Drug: Pregabalin<br>* Pregabalin capsules 75 mg twice daily on Days 1-4, then 150 mg twice daily on Days 5-28<br>|
| Placebo Comparator: Placebo<br> | Drug: Placebo<br>* Matching placebo capsules twice daily for 28 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in polysomnographic (PSG) sleep efficiency in the efficacy evaluable population |  | Endpoint | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in total sleep time |  | Endpoint | 
| Change from baseline in sleep onset latency |  | Endpoint | 
| Change from baseline in wake after sleep onset |  | Endpoint | 
| Change from baseline in percent sleep spent in stages 3 and 4 |  | Endpoint | 
| Change from baseline in percent sleep spent in REM stage |  | Endpoint | 
| Change from baseline in night sleep quality based on Groningen Sleep Questionnaire (GSQ) |  | Endpoint | 
| Change from baseline in 4-week sleep quality (Medical Outcomes Study [MOS] Sleep Scale) |  | Endpoint | 
| Adverse events and laboratory value changes |  | Endpoint |
Efficacy of Tamsulosin Oral-controlled Absorption System (OCAS) in the Treatment of Distal Ureteral Stones

Study Overview
=================
Brief Summary
-----------------
This is a randomized double blind placebo-controlled study that will assess the efficacy of Tamsulosin oral-controlled absorption system (OCAS) 0.4 mg in the conjunctive medical treatment of distal ureteral stones with a size of 4-10 mm compared to placebo in control group.

Detailed Description
-----------------
patient will be randomized to receive placebo or Tamsulosin OCAS 0.4 mg 1 tablet OD for a maximum of 28 days or until the ureteral stone is passed and sodium diclofenac 50 mg twice a day, for 10 days. All patients will receive 75 mg sodium diclofenac via intramuscular on demand

Official Title
-----------------
Efficacy of Tamsulosin OCAS in the Conjunctive Medical Treatment of Distal Ureteral Stones.A Randomized, Double-blind, Placebo-controlled Study

Conditions
-----------------
Ureteral Calculi

Intervention / Treatment
-----------------
* Drug: Tamsulosin Hydrochloride OCAS 0.4 mg
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female patient aged => 18 years. Patients who have distal ureteral stones with a size of 4-10 mm Written informed consent has been obtained. Exclusion Criteria: Patients with history of ureteral surgery Patients with urinary tract infection Patient with diabetes and peptic ulcer Patient with renal dysfunction (elevated of serum creatinine level) Patients with severe hydronephrosis Patients with history of passing stones Pregnancy Patients who desire to withdraw from the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo<br> | Other: Placebo<br>* One tablet OD for a maximum of 28 days<br>|
| Experimental: Tamsulosin Hydrochloride OCAS 0.4 mg<br> | Drug: Tamsulosin Hydrochloride OCAS 0.4 mg<br>* One tablet OD for a maximum of 28 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stone expulsion rate and time. |  | 28 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of diclofenac injection used |  | 28 days | 
| Rate of occurrence of adverse events |  | 28 days |
Thunder-Fire Moxibustion Therapy for Chronic Fatigue Syndrome on Shenque Acupoint: a Randomized Controlled Trial

Study Overview
=================
Brief Summary
-----------------
Chronic fatigue syndrome is a group of syndrome and is prevalent in adult. Thunder-fire moxibustion is a commentary therapy belonged to acupuncture therapy. To evaluate the effect and safety of thunder-fire moxibustion therapy for chronic fatigue syndrome, we apply a randomized controlled trial by recruiting chronic fatigue syndrome patient as subject, applying thunder-fire moxibustion on shenque acupoint contrasted to common moxa-stick moxibustion, taking fatigue rating scale score, the content of CD3+、CD4+、CD8+、CD4+/CD8+ as evaluation indexes. The treatment time is 20-30 minutes per session, 3-4 times a week, there are totally 15 sessions.

Official Title
-----------------
Thunder-Fire Moxibustion Therapy for Chronic Fatigue Syndrome on Shenque Acupoint: a Randomized Controlled Trial

Conditions
-----------------
Chronic Fatigue Syndrome

Intervention / Treatment
-----------------
* Other: thunder-fire moxibustion therapy
* Other: common moxa-stick moxibustion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1.Clinical diagnosis of chronic fatigue syndrome, 2.Age between 18 to 65 years old. 3.Must be able to accept moxibustion treatment 4.Never receive any treatment or has suspended treatment over 2 weeks 5.Patients with good adherence, signed informed consent by themselves Exclusion Criteria: 1.Other primary disease caused by chronic fatigue 2.Pregnancy or breast-feeding women. 3.Merge in other serious diseases, such as severe damage in heart, liver, kidney ,lung or mental illness 4.Has took durg for insomnia treatment 5.Has received acupuncture,massage for chronic fatigue syndrome treatment 6.Suffered from infectious disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: TFM<br>thunder-fire moxibustion therapy | Other: thunder-fire moxibustion therapy<br>* burn moxa stick and heat shenque acupoint<br>|
| Active Comparator: MSM<br>common moxa-stick moxibustion therapy | Other: common moxa-stick moxibustion<br>* burn moxa stick and heat shenque acupoint<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fatigue rating scale score |  | 5 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| content of peripheral t-lymphocyte subsets |  | 3 minutes |